The second batch of Pfizer vaccine documents from the FDA has been released (11,043 pages), as well as an unredacted version of the post-marketing experience report (below).
These documents can be downloaded from http://phmpt.org/pfizers-documents/
(updated 7 April 2022)
5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT
REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021
reissue_5.3.6-postmarketing-experience
A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS
C4591001_Clinical_Protocol_Nov2020_Pfizer_BioNTech
SAFETY DATA SHEET
PF00092_MTR_PFEM_EN
CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT
REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021
5.3.6-postmarketing-experience